Graying China Presents New Trajectories For Health Players
China's latest national census data paint a mixed picture for the provision of health in the world’s most populous nation, with multiple major trends potentially impacting areas of opportunity.
You may also be interested in...
The antibody-drug conjugate market is emerging as the next battleground for intense competition in China, with global partnerships becoming essential to win, as evidenced by a major new alliance between Innovent and Sanofi.
Where once there were promising prospects for cross-strait collaboration, biopharma firms in mainland China and Taiwan may now find themselves looking elsewhere for partners following a controversial visit to Taipei by US House Speaker Nancy Pelosi.
China’s Center for Drug and Evaluation has issued new guidance on the development of new vaccines and drugs for COVID-19 in which it backs antivirals as a key weapon, while the Politburo has shown no signs of backing away from the country's tough "COVID Zero" policies.